|1.||Selgas, Rafael: 1 article (01/2014)|
|2.||Quirce, Santiago: 1 article (01/2014)|
|3.||Rodríguez-Gayo, Lucía: 1 article (01/2014)|
|4.||Alvarez, Laura: 1 article (01/2014)|
|5.||González, Elena: 1 article (01/2014)|
|6.||Sánchez-Villanueva, Rafael J: 1 article (01/2014)|
|7.||Bajo, M Auxiliadora: 1 article (01/2014)|
|8.||Díaz, Raquel: 1 article (01/2014)|
|9.||Menéndez, David: 1 article (01/2014)|
|10.||Stolić, Radoica: 1 article (01/2007)|
06/01/1990 - "Results of the study show that hypoxemia during acetate dialysis with cuprophan membranes is not accompanied by changes of PcjO2 and therefore by changes in cerebral oxygenation. "
03/01/1985 - "However, the degree of hypoxemia was twice as great with a cuprophan membrane primed with acetate (18.6 +/- 3.3 mm Hg) compared with air or bicarbonate (9.1 +/- 1.4 and 7.0 +/- 2.0 mm Hg, respectively), or compared with PAN (8 +/- 2.8 mm Hg). "
10/01/1985 - "Our data demonstrate that complement activation is not the only possible mechanism responsible for early leukopenia (as well as hypoxemia) during dialysis with cuprophan membranes."
05/01/1988 - "Bicarbonate dialysate, compared with acetate, eliminated hypoxemia in cellulose acetate membranes and reduced its degree and duration with cuprophane. "
12/01/1986 - "To further elucidate the mechanisms responsible for the hypoxemia we studied ventilation, pulmonary gas exchanges, blood gas pressures and exchanges of CO2-T, CO2-D and HCO-3 in six patients during AD and BD on 1 m2 cuprophan filter and during BF on 1.2 m2 polyacrylonitrile filter. "
|2.||Acute Kidney Injury (Acute Renal Failure)
01/01/1998 - "However, while waiting further information, we would advocate to abandon the use of cuprophane to dialyze patients with acute renal failure."
01/01/1996 - "Only cost is in favour of the use of cuprophane membranes, especially in patients with acute renal failure."
02/01/1990 - "MP boluses (30 mg/kg) were given to 10 consenting patients suffering from acute renal failure, immediately before blood started to circulate through a hollow-fiber Cuprophan dialyzer. "
01/01/1998 - "Several recent publications have suggested that the use of cuprophane in the setting of acute renal failure is associated with a higher mortality (especially from sepsis) and a slower recovery of renal function in the survivors in comparison with more biocompatible membranes. "
10/16/1999 - "There were no differences in outcome for patients with dialysis-dependent acute renal failure between those treated with Cuprophan membranes and those treated with polymethyl-methacrylate membranes."
07/01/1990 - "Cuprophan induces the most profound leukopenia, and also induces the most pronounced leukocytosis. "
08/01/1984 - "Recurrent dialysis with new cuprophane and cellulose acetate membranes leads to a decrease in pre-dialysis and "rebound leukocytosis" neutrophil count, as well as a more intense activation of complement and an enhanced endogenous clearance of products of complement activation. "
07/01/1990 - "The leukocytosis occurs with both low and high biocompatible membranes, such as Cuprophan, Hemophan, and Polyamide. "
10/01/1980 - "After 2 and 4 hours of dialysis, a rebound leukocytosis was seen with cuprophan, regenerated cellulose, and cellulose acetate, but not with polyacrilonitrile. "
|5.||Chronic Kidney Failure (Chronic Renal Failure)
12/01/2004 - "Haemodialysis (HD) with bioincompatible cellulosic membranes like Cuprophan (CU) is considered to influence negatively the clinical outcome of acute and chronic renal failure. "
01/01/1995 - "[The influence of multiple use of cuprophan dialysers on hemodynamic changes in children with chronic kidney failure]."
01/01/1993 - "Three patients with chronic renal failure underwent HD with cuprophane membranes. "
01/01/1990 - "Peak expiratory flow rates were measured during routine haemodialysis in 18 patients with chronic renal failure who were in receipt of thrice weekly haemodialysis treatment, using both a new cuprophan dialyzer and then the same dialyzer after reprocessing. "
01/01/1988 - "Lung vascular permeability was measured in eight patients with dialysis-dependent chronic renal failure immediately before and during intermittent haemodialysis with cuprophane membranes. "
|3.||Complement System Proteins (Complement)
|4.||Polymethyl Methacrylate (Sol)
|5.||polysulfone P 1700 (UDEL)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Renal Dialysis (Hemodialysis)
|2.||Continuous Ambulatory Peritoneal Dialysis (CAPD)